F. Mentré, X. Panhard, R. Savic, and B. , Vrijens REFERENCES 1. Piliero PJ. Atazanavir: a novel HIV-1 protease inhibitor, Expert Opin Investig Drugs, 2002.

D. Goldsmith and C. Perry, Atazanavir, Drugs, vol.17, issue.9, pp.1679-93, 2003.
DOI : 10.2165/00003495-200363160-00003

S. Colombo, T. Buclin, M. Cavassini, L. Decosterd, A. Telenti et al., Population Pharmacokinetics of Atazanavir in Patients with Human Immunodeficiency Virus Infection, Antimicrobial Agents and Chemotherapy, vol.50, issue.11
DOI : 10.1128/AAC.00098-06

L. Dickinson, M. Boffito, D. Back, L. Waters, L. Else et al., Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers, Journal of Antimicrobial Chemotherapy, vol.63, issue.6, pp.1233-1276, 2009.
DOI : 10.1093/jac/dkp102

C. Solas, M. Gagnieu, I. Ravaux, M. Drogoul, A. Lafeuillade et al., Population Pharmacokinetics of Atazanavir in Human Immunodeficiency Virus-Infected Patients, Therapeutic Drug Monitoring, vol.30, issue.6, pp.670-673, 2008.
DOI : 10.1097/FTD.0b013e3181897bff

P. Cjll, D. Back, T. Blaschke, C. Boucher, C. Fletcher et al., Updated guideline to perform therapeutic drug monitoring for antiretroviral agents, Reviews in Antiviral Therapy, vol.2006, issue.3, pp.4-14, 2006.

L. Tiec, C. Barrail, A. Goujard, C. Taburet, and A. , Clinical Pharmacokinetics and Summary of Efficacy and Tolerability of Atazanavir, Clinical Pharmacokinetics, vol.63, issue.7, pp.1035-50, 2005.
DOI : 10.2165/00003088-200544100-00003

P. Kuehl, J. Zhang, Y. Lin, J. Lamba, M. Assem et al., Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression, Nature Genetics, vol.27, issue.4, pp.383-91, 2001.
DOI : 10.1038/86882

D. Kile, S. Mawhinney, C. Aquilante, J. Rower, J. Castillo-mancilla et al., A Population Pharmacokinetic-Pharmacogenetic Analysis of Atazanavir Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia, AIDS Res Hum Retroviruses J Infect Dis, vol.12, 2005.

T. Blaschke, Variable adherence to prescribed dosing regimens for protease inhibitors: scope and outcomes, Current Opinion in HIV and AIDS, vol.3, issue.6, pp.603-610, 2008.
DOI : 10.1097/COH.0b013e32831271c2

L. Osterberg, J. Urquhart, and T. Blaschke, Understanding Forgiveness: Minding and Mining the Gaps Between Pharmacokinetics and Therapeutics, Clinical Pharmacology & Therapeutics, vol.288, issue.4, 2010.
DOI : 10.1161/01.HYP.0000203309.07140.d3

J. Bae, W. Guyer, K. Grimm, and F. Altice, Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research, AIDS, vol.25, issue.3, pp.279-90, 2011.
DOI : 10.1097/QAD.0b013e328340feb0

D. Bangsberg, S. Perry, E. Charlebois, R. Clark, M. Roberston et al., Nonadherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS Suboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, pp.1181-327, 2001.

G. Lucas, Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven, Journal of Antimicrobial Chemotherapy, vol.55, issue.4, pp.413-419, 2005.
DOI : 10.1093/jac/dki042

B. Roge, T. Barfod, O. Kirk, T. Katzenstein, N. Obel et al., Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study Vrijens B, Goetghebeur E. The impact of compliance in pharmacokinetic studies Stat Methods Med Res Electronic monitoring of variation in drug intakes can reduce bias and improve precision in pharmacokinetic/pharmacodynamic population studies The odds that clinically unrecognized poor or partial adherence confuses population pharmacokinetic/pharmacodynamic analyses Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models, HIV Med. Feb Basic Clin Pharmacol Toxicol. J Clin Pharmacol, vol.58239645, issue.244, pp.344-51247, 1999.

T. Blaschke, L. Osterberg, B. Vrijens, and J. Urquhart, Adherence to Medications: Insights Arising from Studies on the Unreliable Link Between Prescribed and Actual Drug Dosing Histories, Annual Review of Pharmacology and Toxicology, vol.52, issue.1
DOI : 10.1146/annurev-pharmtox-011711-113247

B. Vrijens, E. Goetghebeur, B. Vrijens, E. Goetghebeur, E. De-klerk et al., Comparing compliance patterns between randomized treatments Modelling the association between adherence and viral load in HIV-infected patients, Annu Rev Pharmacol Toxicol Feb Control Clin Trials, vol.10521824, issue.2717, pp.275-301187, 1997.

C. Goujard, A. Barrail-tran, X. Duval, G. Nembot, X. Panhard et al., Virological Response to Atazanavir, Ritonavir and Tenofovir/Emtricitabine: Relation to Individual Pharmacokinetic Parameters and Adherence measured by Medication Events Monitoring System (MEMS) in Naïve HIV-Infected Patients (ANRS134 trial) Internation AIDS Society; Vienna, Austria2010. 29 Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption, J Pharmacokinet Pharmacodyn. Antimicrob Agents Chemother, vol.3452, issue.306, pp.711-262138, 2007.

S. Zvada, J. Van-der-walt, P. Smith, P. Fourie, G. Roscigno et al., Effects of Four Different Meal Types on the Population Pharmacokinetics of Single-Dose Rifapentine in Healthy Male Volunteers, Antimicrobial Agents and Chemotherapy, vol.54, issue.8, pp.3390-3394, 2009.
DOI : 10.1128/AAC.00345-10

S. Shafran, L. Mashinter, S. Roberts, D. Lorenzo, F. Waters et al., The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations Impact of different low-dose ritonavir regimens on lipids, CD36, and adipophilin expression Risk factors for gastrointestinal adverse events in HIV treated and untreated patients, Nov HIV Med. Clin Pharmacol Ther. AIDS Rev, vol.132368511, issue.351, pp.2237-45421, 2005.

J. Harter, C. Peck, and . Chronobiology, Suggestions for integrating it into drug development

L. Lindbom and . Development, PsN-Toolkit???A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM, Computer Methods and Programs in Biomedicine, vol.79, issue.3, pp.241-57, 2005.
DOI : 10.1016/j.cmpb.2005.04.005

*. Note, B. All, and . Wsv, BSV=Between-subject variability, WSV=Within-subject variability, RV=Residual variability, MTT=mean transit time, NN=number of transit compartments, ka=absorption rate constant BSV (CL/F)* 38, pp.31-31

*. Bsv=between-subject-variability and *. *. Rv=residual-variability, CL/F)0=atazanavir CL in absence of ritonavir, MTT=mean transit time, NN=number of transit compartments, ka=absorption rate constant, AUC50 ? ritonavir exposure needed for half maximal boosting effect, Emax ? maximal effect of ritonavir boosting